Bevacizumab Plus Chemotherapy in Patients With Early Stage HER2-Negative Breast Cancer

Summary: Dr. Gunter von Minckwitz discusses the recent paper he authored that showed that bevacizumab in addition to neoadjuvant chemotherapy significantly increased the rate of pathological complete response in patients with early stage HER2-negative breast cancer.